Publications<\/h2>\n\t\t\t\t![\"608_gonzalez2\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2020\/04\/608_gonzalez2.jpg\" "\\"608_gonzalez2\\"")
\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t\u2022 To identify new therapeutic strategies and mechanisms of resistance to current treatments for breast cancer
\n\u2022 To evaluate the role of the RANK signalling pathway in epithelial homeostasis, inflammation and cancer, and its potential as a therapeutic target.\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tMateo,F;He,Z;Mei,L;de Garibay,GR;Herranz,C;Garc\u00eda,N;Lorentzian,A et al, Modification of BRCA1-associated breast cancer risk by HMMR overexpression<\/strong>., Nat. Commun., 2022;13(1):1895-1895, doi:10.1038\/s41467-022-29335-z<\/p>\nVethencourt,A,Trinidad,EM,Petit,A,Soler Monso,MT,Aleza,CG,Urruticochea,A,Garcia Tejedor,A, Martinez,AG, Obadia,V, Vazquez,S, Villanueva,R, Fernanez,A, Cejuela,M, Penabad,SR, Stradella,A, Gil,M, Pernas,S, Gonzalez Suarez,E, Falo,C. First results of the randomized window of opportunity clinical trial D-Biomark: Immunomodulatory effect of denosumab in early breast cancer<\/strong>.Cancer Res.2022.82(4)doi:10.1158\/1538-7445.SABCS21-P2-08-10<\/p>\nStradella,A;Gargallo,P;Cejuela,M;Petit,A;Bosch Schips,J;Carbonell,P;Recalde,S et al, Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma<\/strong>., Mod. Pathol., 2022;35(8):1066-1074, doi:10.1038\/s41379-022-01017-7<\/p>\nCejuela,M;Vethencourt,A;Pernas,S, Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer<\/strong>., Curr. Oncol. Rep., 2022;doi:10.1007\/s11912-022-01339-4<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t16CEE012. PLEIO-RANK: Pleiotropic treatment of cancer: RANK inhibitors targeting cancer stem cells and immunity<\/strong>. COMISSI\u00d3 EUROPEA. Budget: 1999960,01. 2016-2023. PI: Gonz\u00e1lez Su\u00e1rez, Eva.<\/p>\n17PRV003. An open label biomarker pilot study of the antitumoral activity of denosumab in the pre- operative setting of early breast cancer<\/strong>. Amgen Inc. Budget: 517652. 2019-2023. PI: Eva Gonzalez Suarez.<\/p>\n20FIS036. CONTRATOS RIO HORTEGA<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 53732. 2020-2022. PI: Gonz\u00e1lez Su\u00e1rez, Eva.<\/p>\n21PSJ002. Estudio de biomarcadores de la actividad antitumoral del denosumab y su papel como modulador de la respuesta inmune en el c\u00e1ncer de mama precoz: IO-D-BIOMARK. Fundaci\u00f3n Grupo Espa\u00f1ol de Investigaci\u00f3n en Cancer de Mama (GEICAM)<\/strong>. Budget: 42000. 2021-2024. PI: Vethencourt CASADO, Andrea Carolina.<\/p>\n2022-114-1. A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Earlystage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Cancer treated with Neratinib plus Loperamide prophylaxis versus Neratinib with Initial Dose Escalation plus PRN Loperamide prophylaxis versus Neratinib plus Loperamide plus Colesevelam prophylaxis. DIANER Study<\/strong>. Fundaci\u00f3n Grupo Espa\u00f1ol de Investigaci\u00f3n en Cancer de Mama (GEICAM). Budget: 20400. 2022- . PI: Vethencourt CASADO, Andrea Carolina.<\/p>\n\t\t\t\t\tMore Information<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tThe group has received uninterrupted competitive funding from public and private bodies, both nationally and internationally, with a total of 17 grants. Funding agencies include the following: MINECO, ISCIII, AECC, Mutua Madrile\u00f1a Foundation, Marat\u00f3 de TV3, as well as the most prestigious international associations (Concern Foundation (USA), Susan G. Komen Foundation (USA)). It recently received an ERC Consolidator Grant from the European Union, awarded to Dr Gonz\u00e1lez Su\u00e1rez.<\/p>\n
The group has also signed contacts with the industry and coordinates initial-phase clinical trials.<\/p>\n
<\/p>\nReferencia: 682935
\nT\u00edtulo: PLEIO-RANK: Pleiotropic treatment of cancer: RANK inhibitors targeting cancer stem cells and immunity
\nFinanciador: ERC – H2020
\nAgradecimiento: European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program\n
![\"\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2019\/12\/foto1-300x212.jpg\")
<\/p>\nReferencia: SLT006\/17\/00122
\nTipo: “CONTRACTES D’INCORPORACI\u00d3 DE CIENT\u00cdFICS I TECN\u00d2LEGS ALS GRUPS DE RECERCA”
\nFinanciador: DEPARTAMENT DE SALUT
\nAgradecimiento: Departament de Salut de la Generalitat de Catalunya mitjan\u00e7ant l’Acci\u00f3 instrumental d’incorporaci\u00f3 (PERIS).\n
![\"\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2019\/12\/foto2-300x152.jpg\")
<\/p>\n
<\/p>\nReferencia: BES-2015-071675
\nTipo: “AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACI\u00d3N DE DOCTORES 2015”
\nFinanciador: Ministerio de Ciencia, Innovaci\u00f3n y Universidades
\nAgradecimiento: Ministerio de Ciencia, Innovaci\u00f3n y Universidades, perteneciente a la Agencia Estatal de Investigaci\u00f3n (AEI). Cofinanciado por el Fondo Social Europeo. FSE invierte en tu futuro\n
![\"\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2019\/12\/foto3-300x225.jpg\")
<\/p>\n
![\"\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2019\/12\/foto3.1-300x84.png\")
<\/p>\n
<\/p>\nReferencia: PRE2018-086522
\nTipo: “AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACI\u00d3N DE DOCTORES 2018”
\nFinanciador: Ministerio de Ciencia, Innovaci\u00f3n y Universidades
\nAgradecimiento: Ministerio de Ciencia, Innovaci\u00f3n y Universidades, perteneciente a la Agencia Estatal de Investigaci\u00f3n (AEI). Cofinanciado por el Fondo Social Europeo. FSE invierte en tu futuro\n
<\/p>\n
<\/p>\n
<\/p>\nReferencia: IJCI-2017-31564
\nTipo: “AYUDAS JUAN DE LA CIERVA – INCORPORACION 2017”
\nFinanciador: Ministerio de Ciencia, Innovaci\u00f3n y Universidades
\nAgradecimiento: Ministerio de Ciencia, Innovaci\u00f3n y Universidades, perteneciente a la Agencia Estatal de Investigaci\u00f3n (AEI).\n
<\/p>\nReferencia: FJCI-2017-31565
\nTipo: “AYUDAS JUAN DE LA CIERVA – FORMACION 2017”
\nFinanciador: Ministerio de Ciencia, Innovaci\u00f3n y Universidades
\nAgradecimiento: Ministerio de Ciencia, Innovaci\u00f3n y Universidades, perteneciente a la Agencia Estatal de Investigaci\u00f3n (AEI).
\n\nReferencia: IDEAS19093GONZ
\nT\u00edtulo: RANK, instead of RANKL, as a new therapeutic target in Triple Negative Breast Cancer
\nFinanciador: Fundaci\u00f3n Cient\u00edfica de la AECC
\nAgradecimiento: Fundaci\u00f3n Cient\u00edfica de la Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer\n
![\"\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2019\/12\/foto4.jpg\")
<\/p>\nSAF2017-86117-R. New insights in RANK signaling pathway: from biology to treatment
\nPI: Gonz\u00e1lez-Su\u00e1rez, Eva
\nMinisterio de Ciencia, Innovaci\u00f3n y Universidades, perteneciente a la Agencia Estatal de Investigaci\u00f3n (AEI).\n
Cofinanciado por el Fondo Europeo de Desarrollo Regional. FEDER, una manera de hacer Europa. Promover el desarrollo tecnol\u00f3gico, la innovaci\u00f3n y una investigaci\u00f3n de calidad.<\/p>\n
<\/p>\n
![\"\"](\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2019\/12\/foto5-300x78.png\")
<\/p>\n\t\t\t\t![\"Gonzalez](\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/10\/ginzalez-suarez-eva-150x150.jpg\" "\\"ginzalez-suarez-eva\\"")
\n
\n\t\tGonzalez Suarez, Eva\n\t<\/h4>\n\n\t\t\n\t\tegsuarez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\n\n\t\tGonzalez Suarez, Eva\n\t<\/h4>\n\n\t\t\n\t\tegsuarez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\n\t\tRELATED LINKS\n\t<\/h4>\n\n\t\t\n\t\tENBDC\n\t\t<\/a>\n\t<\/h4>\n\n\t\t\n\t\t@EGlezSuarezlab\n\t\t<\/a>\n\t<\/h4>\n\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers \t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t\n- Gonzalez Suarez, Eva<\/li>\n<\/ul>\n\t\t\t\t\t\tClinical researchers \n\t\t\t\t\t\t\t\t\t\t\t
\n- Soler Monso, Maria Teresa<\/li>\n
- Vethencourt Casado, Andrea Carolina<\/li>\n<\/ul>\n
\n\t\tRelated news\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tThe “la Caixa” Foundation promotes a promising study against pancreatic cancer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t24\/11\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tResearchers at CNIO and IDIBELL shed light on the role in lactation of a protein also crucial in breast cancer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t09\/10\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tA connection between senescence and stem cells caused by a breast cancer-initiating protein<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/05\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tXenograft Animal Models Recapitulate Genetic Behavior of Original Human Tumors<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t28\/01\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tScientists discover the immunomodulatory activity of a drug that would improve the efficacy of immunotherapy against breast cancer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/12\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tCommon immune characteristics found in lung metastases to target future treatments<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/07\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tDavid Llobet and Eva Gonz\u00e1lez Su\u00e1rez receive AECC grants on World Cancer Research Day<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t24\/09\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tResearchers from IDIBELL confirm the validity of xenographic models for studies of methylation and chemoresistance in breast cancer<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/07\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL researchers relate the amplification of a chromosomal region with resistance to a chemotherapeutic drug in breast cancer<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/06\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tChemoresistance in breast cancer is associated with the modulation of tumor cell populations<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t27\/04\/2017\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"Transformation and Metastasis Summary This group’s research aims to identify new therapeutic targets for cancer which can be directly translated into effective prevention or treatment strategies. Its aim is to understand the signalling pathways involved in the epithelial stem cell fate and homeostasis, their alterations during cancer and metastasis, and the interactions between tumour cells […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-05 12:57:14","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2364"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=2364"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2364\/revisions"}],"predecessor-version":[{"id":23396,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2364\/revisions\/23396"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=2364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Vethencourt,A,Trinidad,EM,Petit,A,Soler Monso,MT,Aleza,CG,Urruticochea,A,Garcia Tejedor,A, Martinez,AG, Obadia,V, Vazquez,S, Villanueva,R, Fernanez,A, Cejuela,M, Penabad,SR, Stradella,A, Gil,M, Pernas,S, Gonzalez Suarez,E, Falo,C. First results of the randomized window of opportunity clinical trial D-Biomark: Immunomodulatory effect of denosumab in early breast cancer<\/strong>.Cancer Res.2022.82(4)doi:10.1158\/1538-7445.SABCS21-P2-08-10<\/p>\n Stradella,A;Gargallo,P;Cejuela,M;Petit,A;Bosch Schips,J;Carbonell,P;Recalde,S et al, Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma<\/strong>., Mod. Pathol., 2022;35(8):1066-1074, doi:10.1038\/s41379-022-01017-7<\/p>\n Cejuela,M;Vethencourt,A;Pernas,S, Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer<\/strong>., Curr. Oncol. Rep., 2022;doi:10.1007\/s11912-022-01339-4<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t 16CEE012. PLEIO-RANK: Pleiotropic treatment of cancer: RANK inhibitors targeting cancer stem cells and immunity<\/strong>. COMISSI\u00d3 EUROPEA. Budget: 1999960,01. 2016-2023. PI: Gonz\u00e1lez Su\u00e1rez, Eva.<\/p>\n 17PRV003. An open label biomarker pilot study of the antitumoral activity of denosumab in the pre- operative setting of early breast cancer<\/strong>. Amgen Inc. Budget: 517652. 2019-2023. PI: Eva Gonzalez Suarez.<\/p>\n 20FIS036. CONTRATOS RIO HORTEGA<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 53732. 2020-2022. PI: Gonz\u00e1lez Su\u00e1rez, Eva.<\/p>\n 21PSJ002. Estudio de biomarcadores de la actividad antitumoral del denosumab y su papel como modulador de la respuesta inmune en el c\u00e1ncer de mama precoz: IO-D-BIOMARK. Fundaci\u00f3n Grupo Espa\u00f1ol de Investigaci\u00f3n en Cancer de Mama (GEICAM)<\/strong>. Budget: 42000. 2021-2024. PI: Vethencourt CASADO, Andrea Carolina.<\/p>\n 2022-114-1. A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Earlystage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Cancer treated with Neratinib plus Loperamide prophylaxis versus Neratinib with Initial Dose Escalation plus PRN Loperamide prophylaxis versus Neratinib plus Loperamide plus Colesevelam prophylaxis. DIANER Study<\/strong>. Fundaci\u00f3n Grupo Espa\u00f1ol de Investigaci\u00f3n en Cancer de Mama (GEICAM). Budget: 20400. 2022- . PI: Vethencourt CASADO, Andrea Carolina.<\/p>\n\t\t\t\t\tMore Information<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t The group has received uninterrupted competitive funding from public and private bodies, both nationally and internationally, with a total of 17 grants. Funding agencies include the following: MINECO, ISCIII, AECC, Mutua Madrile\u00f1a Foundation, Marat\u00f3 de TV3, as well as the most prestigious international associations (Concern Foundation (USA), Susan G. Komen Foundation (USA)). It recently received an ERC Consolidator Grant from the European Union, awarded to Dr Gonz\u00e1lez Su\u00e1rez.<\/p>\n The group has also signed contacts with the industry and coordinates initial-phase clinical trials.<\/p>\n <\/p>\nReferencia: 682935 <\/p>\nReferencia: BES-2015-071675 <\/p>\nReferencia: PRE2018-086522 <\/p>\nReferencia: IJCI-2017-31564 Cofinanciado por el Fondo Europeo de Desarrollo Regional. FEDER, una manera de hacer Europa. Promover el desarrollo tecnol\u00f3gico, la innovaci\u00f3n y una investigaci\u00f3n de calidad.<\/p>\n Transformation and Metastasis Summary This group’s research aims to identify new therapeutic targets for cancer which can be directly translated into effective prevention or treatment strategies. Its aim is to understand the signalling pathways involved in the epithelial stem cell fate and homeostasis, their alterations during cancer and metastasis, and the interactions between tumour cells […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-05 12:57:14","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2364"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=2364"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2364\/revisions"}],"predecessor-version":[{"id":23396,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2364\/revisions\/23396"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=2364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nT\u00edtulo: PLEIO-RANK: Pleiotropic treatment of cancer: RANK inhibitors targeting cancer stem cells and immunity
\nFinanciador: ERC – H2020
\nAgradecimiento: European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program\n<\/p>\nReferencia: SLT006\/17\/00122
\nTipo: “CONTRACTES D’INCORPORACI\u00d3 DE CIENT\u00cdFICS I TECN\u00d2LEGS ALS GRUPS DE RECERCA”
\nFinanciador: DEPARTAMENT DE SALUT
\nAgradecimiento: Departament de Salut de la Generalitat de Catalunya mitjan\u00e7ant l’Acci\u00f3 instrumental d’incorporaci\u00f3 (PERIS).\n<\/p>\n
\nTipo: “AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACI\u00d3N DE DOCTORES 2015”
\nFinanciador: Ministerio de Ciencia, Innovaci\u00f3n y Universidades
\nAgradecimiento: Ministerio de Ciencia, Innovaci\u00f3n y Universidades, perteneciente a la Agencia Estatal de Investigaci\u00f3n (AEI). Cofinanciado por el Fondo Social Europeo. FSE invierte en tu futuro\n<\/p>\n<\/p>\n
\nTipo: “AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACI\u00d3N DE DOCTORES 2018”
\nFinanciador: Ministerio de Ciencia, Innovaci\u00f3n y Universidades
\nAgradecimiento: Ministerio de Ciencia, Innovaci\u00f3n y Universidades, perteneciente a la Agencia Estatal de Investigaci\u00f3n (AEI). Cofinanciado por el Fondo Social Europeo. FSE invierte en tu futuro\n<\/p>\n<\/p>\n
\nTipo: “AYUDAS JUAN DE LA CIERVA – INCORPORACION 2017”
\nFinanciador: Ministerio de Ciencia, Innovaci\u00f3n y Universidades
\nAgradecimiento: Ministerio de Ciencia, Innovaci\u00f3n y Universidades, perteneciente a la Agencia Estatal de Investigaci\u00f3n (AEI).\n<\/p>\nReferencia: FJCI-2017-31565
\nTipo: “AYUDAS JUAN DE LA CIERVA – FORMACION 2017”
\nFinanciador: Ministerio de Ciencia, Innovaci\u00f3n y Universidades
\nAgradecimiento: Ministerio de Ciencia, Innovaci\u00f3n y Universidades, perteneciente a la Agencia Estatal de Investigaci\u00f3n (AEI).
\n\nReferencia: IDEAS19093GONZ
\nT\u00edtulo: RANK, instead of RANKL, as a new therapeutic target in Triple Negative Breast Cancer
\nFinanciador: Fundaci\u00f3n Cient\u00edfica de la AECC
\nAgradecimiento: Fundaci\u00f3n Cient\u00edfica de la Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer\n<\/p>\nSAF2017-86117-R. New insights in RANK signaling pathway: from biology to treatment
\nPI: Gonz\u00e1lez-Su\u00e1rez, Eva
\nMinisterio de Ciencia, Innovaci\u00f3n y Universidades, perteneciente a la Agencia Estatal de Investigaci\u00f3n (AEI).\n<\/p>\n<\/p>\n\t\t\t\t\n\n\t\tGonzalez Suarez, Eva\n\t<\/h4>\n
\n\t\t\n\t\tegsuarez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t
\n\n\t\tGonzalez Suarez, Eva\n\t<\/h4>\n
\n\t\t\n\t\tegsuarez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tRELATED LINKS\n\t<\/h4>\n
\n\t\t\n\t\tENBDC\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@EGlezSuarezlab\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers \t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n\t\tRelated news\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tThe “la Caixa” Foundation promotes a promising study against pancreatic cancer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t24\/11\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tResearchers at CNIO and IDIBELL shed light on the role in lactation of a protein also crucial in breast cancer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t09\/10\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tA connection between senescence and stem cells caused by a breast cancer-initiating protein<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/05\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tXenograft Animal Models Recapitulate Genetic Behavior of Original Human Tumors<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t28\/01\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tScientists discover the immunomodulatory activity of a drug that would improve the efficacy of immunotherapy against breast cancer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/12\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tCommon immune characteristics found in lung metastases to target future treatments<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/07\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tDavid Llobet and Eva Gonz\u00e1lez Su\u00e1rez receive AECC grants on World Cancer Research Day<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t24\/09\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tResearchers from IDIBELL confirm the validity of xenographic models for studies of methylation and chemoresistance in breast cancer<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/07\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL researchers relate the amplification of a chromosomal region with resistance to a chemotherapeutic drug in breast cancer<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/06\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tChemoresistance in breast cancer is associated with the modulation of tumor cell populations<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t27\/04\/2017\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"